Conference abstract · 8 Apr 2015
Conference abstractPublished 21 Nov 2013
Development of nanoparticle encapsulated miR-107 as an anti-cancer therapeutic for head and neck cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide with about 600,000 new cases diagnosed in the last year. The 5-year survival rate of HNSCC has remained stagnant despite advances in the clinical management of this disease. Understanding the molecular pathways that lead to aggressive HNSCC is crucial to identify new �druggable� targets for anti-cancer drug development. Our laboratory showed that miR-107 expression is reduced and functions as a tumor suppressor gene in HNSCC suggesting the potential application of miR-107 as a novel anti-cancer therapeutic. In this study, we determined the efficiency and efficacy of cationic lipid nanoparticles to deliver pre-miR-107 (NP/pre-miR-107) in HNSCC cells in vitro and in vivo. NP/pre-miR-107 increased delivery of miR-107 into HNSCC cells by greater than 80,000- fold compared to free pre-miR-107. Levels of known miR-107 targets, PKCÃ?µ, CDK6, and HIF1-Ã?², decreased following NP/pre- miR-107 treatment. Clonogenic survival, cell invasion, and cell migration of HNSCC cells was inhibited with NP/pre-miR-107. Moreover, NP/pre-miR-107 reduced the cancer initiating cell population and dampened the expression of the core embryonic stem cell transcription factors, Nanog, Oct3/4, and Sox2. In a pre-clinical mouse model of HNSCC, systemic administration of NP/pre-miR-107 significantly retarded tumor growth by 45.2% compared to NP/pre-miR-control (p<0.005, n=7). Kaplan-Meir analysis showed a survival advantage for the NP/pre-miR-107 treatment group (p=0.017). Our results demonstrate that cationic lipid nanoparticles are an effective carrier approach to deliver therapeutic miRs to HNSCC.
Subjects
ENT & OtolaryngologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 25 Aug 2012
Molecular Targeted Therapies for Head and Neck Cancer: A New Era in DNA-based Therapeutics
Conference abstract · 20 Jul 2015
Measuring health-related quality of life impacts among head and neck cancer patients of a developing country
Conference abstract · 17 Nov 2015
Targeted Drug Delivery System (TDDS): Encapsulating newly synthesized anti-cancer compoundsconjugated gold nanoparticles
Mini review · 28 Jan 2025
Advancements in Surgical Techniques for Head and Neck Cancer
More from this journal
The newest in Otolaryngology: Open Access.
Research article · 16 Feb 2026
Uninduced Hearing Loss in Animals-A Systematic Literature Review
Short communication · 1 Dec 2025
Chronic Rhinosinusitis: Personalized Medicine, Surgery, and Recurrence
Editorial · 1 Dec 2025
Cochlear Implants and Vestibular Rehabilitation: Integrated Outcomes
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalOtolaryngology: Open Access
- SubjectENT & Otolaryngology
- BylineArticles whose byline prints “Quintin Pan”
